Cefazolin Subcutaneous Microdialysis in Morbidly Obese Patients
NCT ID: NCT01309152
Last Updated: 2013-01-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
16 participants
OBSERVATIONAL
2011-01-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antibiotics Distribution Study in Peripheral Compartments: Contribution of Microdialysis
NCT07327502
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
NCT05205486
Cefazolin PK Study 3g vs 2g
NCT05309304
An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates
NCT00850122
Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis
NCT06005168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 20-25
* undergoing laparoscopic gastric banding, or bypass surgery or sleeve gastrectomy (See population description for surgery type of the non-obese group)
* 21-60 years old
* American Society of Anaesthesiologists (ASA) physical status II to III
Exclusion Criteria
* breastfeeding
* known allergy for cefazolin/nadroparin
* known ejection fraction of \< 35%
* renal insufficiency
21 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Antonius Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
St. Antonius Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Antonius Hospital
Nieuwegein, Utrecht, Netherlands
St Antonius Hospital
Nieuwegein, , Netherlands
St. antonius hospital
Nieuwegein, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Diepstraten J, Janssen EJ, Hackeng CM, van Dongen EP, Wiezer RJ, van Ramshorst B, Knibbe CA. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol. 2015 Jan;71(1):25-34. doi: 10.1007/s00228-014-1760-4. Epub 2014 Oct 12.
Brill MJ, Houwink AP, Schmidt S, Van Dongen EP, Hazebroek EJ, van Ramshorst B, Deneer VH, Mouton JW, Knibbe CA. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2014 Mar;69(3):715-23. doi: 10.1093/jac/dkt444. Epub 2013 Nov 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LTME/VL-10.14/MICK
Identifier Type: -
Identifier Source: secondary_id
MICK R-10.29A/MICK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.